NasdaqGM:NAMSBiotechs
Should NewAmsterdam’s Multi-Indication Obicetrapib Strategy Reshape How NAMS Investors View Pipeline Concentration?
NewAmsterdam Pharma recently outlined its late-stage plans for obicetrapib, including an expected EMA approval decision in the second half of 2026, first-patient dosing in the RUBENS Phase 3 metabolic syndrome trial, continued progress in the PREVAIL cardiovascular outcomes study, and preparations for an Alzheimer’s disease trial based on earlier biomarker data.
These updates give investors clearer visibility into NewAmsterdam’s pipeline evolution across cardiometabolic and neurological...